Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Chieh‐Hsin Lin, Ching-Hua Lin, Yue-Cune Chang, et al.
Biological Psychiatry (2017) Vol. 84, Iss. 6, pp. 422-432
Closed Access | Times Cited: 125

Showing 26-50 of 125 citing articles:

Astrocytic Regulation of Glutamate Transmission in Schizophrenia
Yu-Ying Mei, Dong Wu, Ning Zhou
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 57
Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist
Henry A. Nasrallah, Rissa Fedora, R. F. Morton
Schizophrenia Research (2019) Vol. 208, pp. 217-220
Closed Access | Times Cited: 52
The gut-microbiome as a target for the treatment of schizophrenia: A systematic review and meta-analysis of randomised controlled trials of add-on strategies
Amedeo Minichino, Natascia Brondino, Marco Solmi, et al.
Schizophrenia Research (2020) Vol. 234, pp. 58-70
Open Access | Times Cited: 43
Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials
Kah Kheng Goh, Tzu‐Hua Wu, Chun-Hsin Chen, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 3, pp. 236-252
Closed Access | Times Cited: 41
Characteristics and definitions of ultra-treatment-resistant schizophrenia – A systematic review and meta-analysis
Mattia Campana, Peter Falkai, Dan Siskind, et al.
Schizophrenia Research (2021) Vol. 228, pp. 218-226
Open Access | Times Cited: 40
Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment
Chung-Chieh Hung, Chieh‐Hsin Lin, Hsien‐Yuan Lane
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9718-9718
Open Access | Times Cited: 36
Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis
Damien Etchecopar‐Etchart, Dong Keon Yon, Piotr Wojciechowski, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102473-102473
Open Access | Times Cited: 6
Diet-Related Metabolic Perturbations of Gut Microbial Shikimate Pathway-Tryptamine-tRNA Aminoacylation-Protein Synthesis in Human Health and Disease
Elena L. Paley
International Journal of Tryptophan Research (2019) Vol. 12
Open Access | Times Cited: 42
Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene
J. Alexander Bodkin, Michael J. Coleman, Laura Godfrey, et al.
Biological Psychiatry (2019) Vol. 86, Iss. 7, pp. 523-535
Open Access | Times Cited: 38
The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia
Chieh‐Hsin Lin, Hsien‐Yuan Lane
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 37
Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia
Ju-Chun Pei, Da-Zhong Luo, Shiang-Shin Gau, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 32
Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets
Matej Ľupták, Danica Michaličková, Zdeněk Fišar, et al.
World Journal of Psychiatry (2021) Vol. 11, Iss. 7, pp. 277-296
Open Access | Times Cited: 30
8-Hydroxy-2’-Deoxyguanosine and Reactive Oxygen Species as Biomarkers of Oxidative Stress in Mental Illnesses: A Meta-Analysis
Xue Xin Goh, Pek Yee Tang, Shiau Foon Tee
Psychiatry Investigation (2021) Vol. 18, Iss. 7, pp. 603-618
Open Access | Times Cited: 30
D-Amino Acids as a Biomarker in Schizophrenia
Kurumi Taniguchi, Haruka Sawamura, Yuka Ikeda, et al.
Diseases (2022) Vol. 10, Iss. 1, pp. 9-9
Open Access | Times Cited: 20
Overcoming clozapine’s adverse events: a narrative review of systematic reviews and meta-analyses
Timothy Tanzer, Betty Pham, Nicola Warren, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 811-831
Closed Access | Times Cited: 4
Decreased free D-aspartate levels in the blood serum of patients with schizophrenia
Martina Garofalo, Giuseppe De Simone, Zoraide Motta, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 4
Combination of G72 Genetic Variation and G72 Protein Level to Detect Schizophrenia: Machine Learning Approaches
Eugene Lin, Chieh‐Hsin Lin, Yi-Lun Lai, et al.
Frontiers in Psychiatry (2018) Vol. 9
Open Access | Times Cited: 36
Recent Advances in the Early Intervention in Schizophrenia: Future Direction from Preclinical Findings
Kenji Hashimoto
Current Psychiatry Reports (2019) Vol. 21, Iss. 8
Closed Access | Times Cited: 35
<p>Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)</p>
Chieh‐Hsin Lin, Hui-Ting Yang, Ping-Kun Chen, et al.
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 509-518
Open Access | Times Cited: 32
Circadian rhythm in negative affect: Implications for mood disorders
Jonathan S. Emens, Alec M. Berman, Saurabh S. Thosar, et al.
Psychiatry Research (2020) Vol. 293, pp. 113337-113337
Open Access | Times Cited: 32
Redox signaling and Alzheimer’s disease: from pathomechanism insights to biomarker discovery and therapy strategy
Yuanyuan Chen, Minchang Wang, Yanni Wang, et al.
Biomarker Research (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 29
D-Serine: A Cross Species Review of Safety
Amir Mohammad Meftah, Hiroshi Hasegawa, Joshua T. Kantrowitz
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 25
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia
Andrea de Bartolomeis, Mariateresa Ciccarelli, Licia Vellucci, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 18, pp. 2035-2052
Closed Access | Times Cited: 19
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia
Tanja Veselinović, Irene Neuner
CNS Drugs (2022) Vol. 36, Iss. 8, pp. 819-858
Open Access | Times Cited: 18
Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for Alzheimer's disease
Hsien‐Yuan Lane, Shi‐Heng Wang, Chieh‐Hsin Lin
Psychiatry and Clinical Neurosciences (2022) Vol. 77, Iss. 2, pp. 102-109
Open Access | Times Cited: 18

Scroll to top